The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees, ...
Travere Therapeutics was first featured on our site on August 14, 2024, when the stock was trading at $8.91. At the time, our ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Vera Therapeutics, Inc. gets FDA accelerated approval for Trutakna in IgA nephropathy, but competition and pricing risk remain. Click for this VERA update.
For 2Q26, Nomura Smid Cap Core Fund Institutional Class shares performed in-line with the Fund's benchmark, the Russell 2500 ...
Investor's Business Daily on MSN
Stock Of The Day XP, The Charles Schwab Of Brazil, Nears Buy Point
Brazil just cut its key interest rate as the Fed hiked.
Investor's Business Daily on MSN
Dow Jones futures rise as oil prices, yields fall before Fed rate hike; will market rally bid bond voyage?
The S&P 500 and Nasdaq undercut key support as oil prices and Treasury yields jumped. How will bonds react to the Federal ...
Clinical Trials Arena on MSN
Vera set up for full approval for Trutakna in IgAN with Phase III win
Vera’s Trutakna was granted FDA accelerated approval in IgAN based on 36-week data.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Travere Therapeutics Inc. stock grades by Barron's. View TVTX fundamental and sentiment analysis powered by MarketGrader.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results